Skip to main content
SpringerLink
Log in

Related disorders of bone

  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Renal osteodystrophy includes a broad spectrum of abnormalities in bone and mineral metabolism. This review article discusses related bone disorders, including calcific uremic arteriolopathy, “osteoporosis” and compromised bone strength, and dialysis-related amyloidosis, as well as the contributing roles of glucocorticoids and metabolic acidosis. Bone disorders in the setting of renal transplantation, including osteoporosis, osteonecrosis, and presistent hyperparathyroidism, are also reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moe SM, Drueke TB. 2004 A bridge to improving healthcare outcomes and quality of life. Am J Kidney Dis 43:552–557.

    PubMed  Google Scholar 

  2. Cunningham J, Sprague SM, Cannata-Andia J et al. 2004 Osteoporosis in chronic kidney disease. Am J Kidney Dis 43:566–571.

    PubMed  Google Scholar 

  3. Selye H. Calciphylaxis. 1962 University of Chicago Press, Chicago, IL.

    Google Scholar 

  4. Coates T, Kirkland GS, Dymock RB et al. 1998 Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32:384–391.

    PubMed  CAS  Google Scholar 

  5. Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. 2000 Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure. Am J Kidney Dis 35:588–597.

    PubMed  CAS  Google Scholar 

  6. Wilmer WA, Magro CM. 2002 Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 15:172–186.

    PubMed  Google Scholar 

  7. Moe SM. 2004 Calcific uremic arteriolopathy: a new look at an old disorder. Nephrol Self-Assessment Program 3:77–83.

    Google Scholar 

  8. Llach F. 2003 The evolving clinical features of calciphylaxis. Kidney Int Suppl: S122–124.

  9. Llach F. 1998 Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? Am J Kidney Dis 32:514–518.

    PubMed  CAS  Google Scholar 

  10. Massry SG, Gordon A, Coburn JW et al. 1970 Vascular calcification and peripheral necrosis in a renal transplant recipient. Reversal of lesions following subtotal parathyroidectomy. Am J Med 49:416–422.

    PubMed  CAS  Google Scholar 

  11. Fox R, Banowsky LH, Cruz AB Jr. 1983 Post-renal transplant calciphylaxis: successful treatment with parathyroidectomy. J Urol 129:362–363.

    PubMed  CAS  Google Scholar 

  12. Goyal S, Huhn KM, Provost TT. 2000 Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: possible aetiological role of chemotherapy. Br J Dermatol 143:1087–1090.

    PubMed  CAS  Google Scholar 

  13. Fine A, Zacharias J. 2002 Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–227.

    PubMed  Google Scholar 

  14. Angelis M, Wong LL, Myers SA, Wong LM. 1997 Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089; discussion 1089–10890.

    PubMed  CAS  Google Scholar 

  15. Budisavljevic MN, Cheek D, Ploth DW. 1996 Calciphylaxis in chronic renal failure. J Am Soc Nephrol 7:978–982.

    PubMed  CAS  Google Scholar 

  16. Mazhar AR, Johnson RJ, Gillen D et al. 2001 Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60:324–332.

    PubMed  CAS  Google Scholar 

  17. Vattikuti R, Towler DA. 2004 Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 286:E686–696.

    Google Scholar 

  18. Giachelli CM. 2004 Vascular calcification mechanisms. J Am Soc Nephrol 15:2959–2964.

    PubMed  Google Scholar 

  19. Rostand SG, Thornley-Brown D. 2001 Soft Tissue Calcification in Chronic Renal Failure. In: Drueke T, Salusky IB, eds. The Spectrum of Renal Osteodystrophy. Oxford University Press, Oxford, pp 345–378.

    Google Scholar 

  20. Ahmed S, O’Neill KD, Hood AF, Evan AP, Moe SM. 2001 Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 37:1267–1276.

    PubMed  CAS  Google Scholar 

  21. Hafner J, Keusch G, Wahl C et al. 1995 Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 33:954–962.

    PubMed  CAS  Google Scholar 

  22. Mawad HW, Sawaya BP, Sarin R, Malluche HH. 1999 Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52:160–166.

    PubMed  CAS  Google Scholar 

  23. Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL. 1998 A case control study of proximal calciphylaxis. Am J Kidney Dis 32:376–383.

    PubMed  CAS  Google Scholar 

  24. Walsh JS, Fairley JA. 1995 Calcifying disorders of the skin. J Am Acad Dermatol 33:693–706; quiz 707–710.

    PubMed  CAS  Google Scholar 

  25. Wilmer WA, Voroshilova O, Singh I, Middendorf DF, Cosio FG. 2001. Transcutaneous oxygen tension in patients with calciphylaxis. Am J Kidney Dis 37:797–806.

    PubMed  CAS  Google Scholar 

  26. Moe SM, Chen NX. 2003 Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatr Nephrol 18:969–975.

    PubMed  Google Scholar 

  27. Don BR, Chin AI. 2003 A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 59:463–470.

    PubMed  CAS  Google Scholar 

  28. Kang AS, McCarthy JT, Rowland C, Farley DR, Van Heerden JA. 2000 Is calciphylaxis best treated surgically or medically? Surgery 128:967–972.

    PubMed  CAS  Google Scholar 

  29. Arch-Ferrer JE, Beenken SW, Rue LW, Bland KI, Diethelm AG. 2003 Therapy for calciphylaxis: an outcome analysis. Surgery 134:941–944; discussion 944–945.

    PubMed  Google Scholar 

  30. Podymow T, Wherrett C, Burns KD. 2001 Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant 16:2176–2180.

    PubMed  CAS  Google Scholar 

  31. Vassa N, Twardowski ZJ, Campbell J. 1994 Hyperbaric oxygen therapy in calciphylaxis-induced skin necrosis in a peritoneal dialysis patient. Am J Kidney Dis 23:878–881.

    PubMed  CAS  Google Scholar 

  32. Dwyer KM, Francis DM, Hill PA, Murphy BF. 2002 Calcific uraemic arteriolopathy: local treatment and hyperbaric oxygen therapy. Nephrol Dial Transplant 17:1148–1149.

    PubMed  Google Scholar 

  33. Cicone JS, Petronis JB, Embert CD, Spector DA. 2004 Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 43:1104–1108.

    PubMed  Google Scholar 

  34. Monney P, Nguyen QV, Perroud H, Descombes E. 2004 Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 19:2130–2132.

    PubMed  Google Scholar 

  35. Sewell LD, Weenig RH, Davis MD, McEvoy MT, Pittelkow MR. 2004 Low-dose tissue plasminogen activator for calciphylaxis. Arch Dermatol 140:1045–1048.

    PubMed  Google Scholar 

  36. Biedunkiewicz B, Tylicki L, Lichodziejewska-Niemierko M, Liberek T, Rutkowski B. 2003 Ozonetherapy in a dialyzed patient with calcific uremic arteriolopathy. Kidney Int 64:367–368.

    PubMed  Google Scholar 

  37. Alem AM, Sherrard DJ, Gillen DL et al. 2000 Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399.

    PubMed  CAS  Google Scholar 

  38. Osteoporosis Prevention, Diagnosis, and Treatment. 2000 NIH Consensus Statement. Vol. 17, pp 1–45.

  39. Marshall D, Johnell O, Wedel H. 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259.

    PubMed  CAS  Google Scholar 

  40. Atsumi K, Kushida K, Yamazaki K et al. 1999 Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287–293.

    PubMed  CAS  Google Scholar 

  41. Jamal SA, Chase C, Goh YI, Richardson R, Hawker GA. 2002 Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 39:843–849.

    PubMed  Google Scholar 

  42. Yamaguchi T, Kanno E, Tsubota J et al. 1996 Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 19:549–555.

    PubMed  CAS  Google Scholar 

  43. Duan Y, De Luca V, Seeman E. 1999 Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J Clin Endocrinol Metab 84:718–722.

    PubMed  CAS  Google Scholar 

  44. Pecovnik Balon B, Hojs R, Zavratnik A, Kos M. 2002 Bone mineral density in patients beginning hemodialysis treatment. Am J Nephrol 22:14–17.

    PubMed  CAS  Google Scholar 

  45. Hsu CY, Cummings SR, McCulloch CE, Chertow GM. 2002 Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int 61:1814–1820.

    PubMed  Google Scholar 

  46. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. 1999 Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084–1093.

    PubMed  CAS  Google Scholar 

  47. Schober HC, Han ZH, Foldes AJ et al. 1998 Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 9:1225–1233.

    PubMed  CAS  Google Scholar 

  48. Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ. 1996 Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 28:515–522.

    PubMed  CAS  Google Scholar 

  49. Taal MW, Masud T, Green D, Cassidy MJ. 1999 Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 14:1922–1928.

    PubMed  CAS  Google Scholar 

  50. National Kidney Foundation. 2003 K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:S1–202.

    Google Scholar 

  51. Barnas U, Schmidt A, Seidl G et al. 2001 A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 37:1247–1252.

    PubMed  CAS  Google Scholar 

  52. Coco M, Rush H. 2000 Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115–1121.

    PubMed  CAS  Google Scholar 

  53. Stehman-Breen CO, Sherrard DJ, Alem AM et al. 2000 Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58:2200–2205.

    PubMed  CAS  Google Scholar 

  54. Lindberg JS, Moe SM. 1999 Osteoporosis in end-stage renal disease. Semin Nephrol 19:115–122.

    PubMed  CAS  Google Scholar 

  55. Salusky IB, Goodman WG. 2001 Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12:1978–1985.

    PubMed  CAS  Google Scholar 

  56. Brandenburg VM, Westenfeld R, Ketteler M. 2004 The fate of bone after renal transplantation. J Nephrol 17:190–204.

    PubMed  Google Scholar 

  57. Grotz WH, Rump LC, Niessen A et al. 1998 Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 66:1004–1008.

    PubMed  CAS  Google Scholar 

  58. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. 2003 Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 17:268–274.

    PubMed  Google Scholar 

  59. Grotz WH, Mundinger FA, Rasenack J et al. 1995 Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 10:2096–2100.

    PubMed  CAS  Google Scholar 

  60. Bagni B, Gilli P, Cavallini A et al. 1994 Continuing loss of vertebral mineral density in renal transplant recipients. Eur J Nucl Med 21:108–112.

    PubMed  CAS  Google Scholar 

  61. Torregrosa JV, Campistol JM, Montesinos M, Pons F, Martinez de Osaba MJ. 1995 Evolution of bone mineral density after renal transplantation: related factors. Nephrol Dial Transplant 10(Suppl 6):111–113.

    PubMed  Google Scholar 

  62. Zingraff J, Drueke T. 1991 Can the nephrologist prevent dialysis-related amyloidosis? Am J Kidney Dis 18:1–11.

    PubMed  CAS  Google Scholar 

  63. Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. 1998 β2-microglobulin in renal disease. J Am Soc Nephrol 9:1723–1735.

    PubMed  CAS  Google Scholar 

  64. Koch KM. 1992 Dialysis-related amyloidosis. Kidney Int 41:1416–1429.

    PubMed  CAS  Google Scholar 

  65. Kleinman KS, Coburn JW. 1989 Amyloid syndromes associated with hemodialysis. Kidney Int 35:567–575.

    PubMed  CAS  Google Scholar 

  66. Floege J, Ketteler M. 2001 β2-microglobulin-derived amyloidosis: an update. Kidney Int Suppl 78:S164–171.

    Google Scholar 

  67. Drueke TB. 2000 β2-microglobulin and amyloidosis. Nephrol Dial Transplant 15(Suppl 1):17–24.

    PubMed  CAS  Google Scholar 

  68. Jadoul M, Garbar C, Noel H et al. 1997 Histological prevalence of β2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int 51:1928–1932.

    PubMed  CAS  Google Scholar 

  69. Kessler M, Netter P, Azoulay E et al. 1992 Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 31:157–162.

    PubMed  CAS  Google Scholar 

  70. Schwalbe S, Holzhauer M, Schaeffer J et al. 1997 β2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis? Kidney Int 52:1077–1083.

    PubMed  CAS  Google Scholar 

  71. Campistol JM, Shirahama T, Abraham CR et al. 1992 Demonstration of plasma proteinase inhibitors in β2-microglobulin amyloid deposits. Kidney Int 42:915–923.

    PubMed  CAS  Google Scholar 

  72. Brancaccio D, Ghiggeri GM, Braidotti P et al. 1995 Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis. J Am Soc Nephrol 6:1262–1270.

    PubMed  CAS  Google Scholar 

  73. Gejyo F, Yamada T, Odani S et al. 1985 A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 129:701–706.

    PubMed  CAS  Google Scholar 

  74. Gorevic PD, Casey TT, Stone WJ et al. 1985 Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 76:2425–2429.

    PubMed  CAS  Google Scholar 

  75. Schwarz A, Keller F, Seyfert S et al. 1984 Carpal tunnel syndrome: a major complication in long-term hemodialysis patients. Clin Nephrol 22:133–137.

    PubMed  CAS  Google Scholar 

  76. D’Arcy CA, McGee S. 2000 The rational clinical examination. Does this patient have carpal tunnel syndrome? JAMA 283:3110–3117.

    PubMed  CAS  Google Scholar 

  77. Danesh F, Ho LT. 2001 Dialysis-related amyloidosis: history and clinical manifestations. Semin Dial 14:80–85.

    PubMed  CAS  Google Scholar 

  78. Kuntz D, Naveau B, Bardin T et al. 1984 Destructive spondyloarthropathy in hemodialyzed patients. A new syndrome. Arthritis Rheum 27:369–375.

    PubMed  CAS  Google Scholar 

  79. Bindi P, Chanard J. 1990 Destructive spondyloarthropathy in dialysis patients: an overview. Nephron 55:104–109.

    PubMed  CAS  Google Scholar 

  80. Maruyama H, Gejyo F, Arakawa M. 1992 Clinical studies of destructive spondyloarthropathy in long-term hemodialysis patients. Nephron 61:37–44.

    PubMed  CAS  Google Scholar 

  81. Ohashi K, Hara M, Kawai R et al. 1992 Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int 41:1646–1652.

    PubMed  CAS  Google Scholar 

  82. Allard JC, Artze ME, Porter G et al. 1992 Fatal destructive cervical spondyloarthropathy in two patients on long-term dialysis. Am J Kidney Dis 19:81–85.

    PubMed  CAS  Google Scholar 

  83. Jadoul M, Garbar C, van Ypersele de Strihou C. 2001 Pathological aspects of β2-microglobulin amyloidosis. Semin Dial 14:86–89.

    PubMed  CAS  Google Scholar 

  84. Assounga AG, Bascoul S, Canaud B et al. 1990 A study of β2-microglobulin skin deposits in dialyzed patients and healthy controls. Am J Kidney Dis 15:556–561.

    PubMed  CAS  Google Scholar 

  85. Jadoul M, Malghem J, Vande Berg B, van Ypersele de Strihou C. 1993 Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: a cross-sectional and longitudinal study. Nephrol Dial Transplant 8:1104–1109.

    PubMed  CAS  Google Scholar 

  86. Ketteler M, Koch KM, Floege J. 2001 Imaging techniques in the diagnosis of dialysis-related amyloidosis. Semin Dial 14:90–93.

    PubMed  CAS  Google Scholar 

  87. Copley JB, Lindberg JS. 2001 Nontransplant therapy for dialysis-related amyloidosis. Semin Dial 14:94–98.

    PubMed  CAS  Google Scholar 

  88. Takenaka R, Fukatsu A, Matsuo S et al. 1992 Surgical treatment of hemodialysis-related shoulder arthropathy. Clin Nephrol 38:224–230.

    PubMed  CAS  Google Scholar 

  89. Jaradat MI, Moe SM. 2001 Effect of hemodialysis membranes on β2-microglobulin amyloidosis. Semin Dial 14:107–112.

    PubMed  CAS  Google Scholar 

  90. Schiffl H, Fischer R, Lang SM, Mangel E. 2000 Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 15:840–845.

    PubMed  CAS  Google Scholar 

  91. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J. 1991 Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 39:1012–1019.

    PubMed  Google Scholar 

  92. Kuchle C, Fricke H, Held E, Schiffl H. 1996 High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 16:484–488.

    PubMed  CAS  Google Scholar 

  93. Ameer GA. 2001 Modalities for the removal of β2-microglobulin from blood. Semin Dial 14:103–106.

    PubMed  CAS  Google Scholar 

  94. Jadoul M, Garbar C, Vanholder R et al. 1998 Prevalence of histological β2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int 54:956–959.

    PubMed  CAS  Google Scholar 

  95. Benz RL, Siegfried JW, Teehan BP. 1988 Carpal tunnel syndrome in dialysis patients: comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations. Am J Kidney Dis 11:473–476.

    PubMed  CAS  Google Scholar 

  96. Nakazawa R, Azuma N, Suzuki M et al. 1993 A new treatment for dialysis-related amyloidosis with β2-microglobulin adsorbent column. Int J Artif Organs 16:823–829.

    PubMed  CAS  Google Scholar 

  97. Akizawa T, Kinugasa E, Kitaoka T et al. 1987 Removal of β-2-microglobulin by direct hemoperfusion with a newly developed adsorbent. ASAIO Trans 33:532–537.

    PubMed  CAS  Google Scholar 

  98. Locatelli F, Marcelli D, Conte F et al. 1999 Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 55:286–293.

    PubMed  CAS  Google Scholar 

  99. Mourad G, Argiles A. 1996 Renal transplantation relieves the symptoms but does not reverse β2-microglobulin amyloidosis. J Am Soc Nephrol 7:798–804.

    PubMed  CAS  Google Scholar 

  100. Bardin T, Lebail-Darne JL, Zingraff J et al. 1995 Dialysis arthropathy: outcome after renal transplantation. Am J Med 99:243–248.

    PubMed  CAS  Google Scholar 

  101. Tan SY, Irish A, Winearls CG et al. 1996 Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 50:282–289.

    PubMed  CAS  Google Scholar 

  102. Campistol JM, Ponz E, Munoz-Gomez J et al. 1992 Renal transplantation for dialysis amyloidosis. Transplant Proc 24:118–119.

    PubMed  CAS  Google Scholar 

  103. Campistol JM. 2001 Dialysis-related amyloidosis after renal transplantation. Semin Dial 14:99–102.

    PubMed  CAS  Google Scholar 

  104. Jadoul M, Malghem J, Pirson Y, Maldague B, van Ypersele de Strihou C. 1989 Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy. Clin Nephrol 32:194–197.

    PubMed  CAS  Google Scholar 

  105. Kessler M, Aymard B, Pourel J. 1994 Persistence of β2-microglobulin amyloid 10 years after renal transplantation. Nephrol Dial Transplant 9:333–334.

    PubMed  CAS  Google Scholar 

  106. Wolfe RA, Ashby VB, Milford EL et al. 1999 Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725–1730.

    PubMed  CAS  Google Scholar 

  107. Sprague SM, Josephson MA. 2004 Bone disease after kidney transplantation. Semin Nephrol 24:82–90.

    PubMed  Google Scholar 

  108. Fan SL, Cunningham J. 2005 Bone Disease after Kidney Transplantation. In: Compston J, Shane E, eds. Bone Disease of Organ Transplantation. Elsevier Academic Press, Oxford, pp 221–242.

    Google Scholar 

  109. Heaf JG. 2003 Bone disease after renal transplantation. Transplantation 75:315–325.

    PubMed  Google Scholar 

  110. Gill JS, Tonelli M, Mix CH, Pereira BJ. 2003 The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 14:1636–1642.

    PubMed  Google Scholar 

  111. Vautour LM, Melton LJ 3rd, Clarke BL et al. 2004 Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 15:160–167.

    PubMed  Google Scholar 

  112. Ball AM, Gillen DL, Sherrard D et al. 2002 Risk of hip fracture among dialysis and renal transplant recipients. JAMA 288:3014–3018.

    PubMed  Google Scholar 

  113. Julian BA, Laskow DA, Dubovsky J et al. 1991 Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544–550.

    PubMed  CAS  Google Scholar 

  114. Yazawa K, Ishikawa T, Ichikawa Y et al. 1998 Positive effects of kidney transplantation on bone mass. Transplant Proc 30:3031–3033.

    PubMed  CAS  Google Scholar 

  115. Moreno A, Torregrosa JV, Pons F et al. 1999 Bone mineral density after renal transplantation: long-term follow-up. Transplant Proc 31:2322–2323.

    PubMed  CAS  Google Scholar 

  116. Manolagas SC, Weinstein RS. 1999 New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061–1066.

    PubMed  CAS  Google Scholar 

  117. Khwaja K, Asolati M, Harmon J et al. 2004 Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 4:980–987.

    PubMed  Google Scholar 

  118. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. 2003 Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 3:306–311.

    PubMed  CAS  Google Scholar 

  119. Schneider AE, Zaidi M, Epstein S. 2005 Molecular Effects of Calcineurin Inhibitors. In: Compston J, Shane E, eds. Bone Disease of Organ Transplantation. Elsevier Academic Press, Oxford, pp 79–90.

    Google Scholar 

  120. Stewart PJ, Green OC, Stern PH. 1986 Cyclosporine A inhibits calcemic hormone-induced bone resorption in vitro. J Bone Miner Res 1:285–291.

    PubMed  CAS  Google Scholar 

  121. Chowdhury MH, Shen V, Dempster DW. 1991 Effects of cyclosporine A on chick osteoclasts in vitro. Calcif Tissue Int 49:275–279.

    PubMed  CAS  Google Scholar 

  122. Movsowitz C, Epstein S, Ismail F, Fallon M, Thomas S. 1989 Cyclosporin A in the oophorectomized rat: unexpected severe bone resorption. J Bone Miner Res 4:393–398.

    PubMed  CAS  Google Scholar 

  123. Cvetkovic M, Mann GN, Romero DF et al. 1994 The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57:1231–1237.

    PubMed  CAS  Google Scholar 

  124. Abdelhadi M, Ericzon BG, Hultenby K et al. 2002 Structural skeletal impairment induced by immunosuppressive therapy in rats: cyclosporine A vs tacrolimus. Transplant Int 15:180–187.

    CAS  Google Scholar 

  125. Katz IA, Takizawa M, Jaffe, II et al. 1991 Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. Transplantation 52:571–574.

    PubMed  CAS  Google Scholar 

  126. Cohen A, Sambrook P, Shane E. 2004 Management of bone loss after organ transplantation. J Bone Miner Res 19:1919–1932.

    PubMed  Google Scholar 

  127. Fan SL, Almond MK, Ball E, Evans K, Cunningham J. 2000 Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57:684–690.

    PubMed  CAS  Google Scholar 

  128. Fan SL, Kumar S, Cunningham J. 2003 Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 63:2275–2279.

    PubMed  CAS  Google Scholar 

  129. Grotz W, Nagel C, Poeschel D et al. 2001 Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12:1530–1537.

    PubMed  CAS  Google Scholar 

  130. Arlen DJ, Lambert K, Ioannidis G, Adachi JD. 2001 Treatment of established bone loss after renal transplantation with etidronate. Transplantation 71:669–673.

    PubMed  CAS  Google Scholar 

  131. Haas M, Leko-Mohr Z, Roschger P et al. 2003 Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63:1130–1136.

    PubMed  CAS  Google Scholar 

  132. Palmer SC, Strippoli GF, McGregor DO. 2005 Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 45:638–649.

    PubMed  Google Scholar 

  133. Coco M, Glicklich D, Faugere MC et al. 2003 Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14:2669–2676.

    PubMed  CAS  Google Scholar 

  134. Weber TJ, Quarles LD. 2000 Preventing bone loss after renal transplantation with bisphosphonates: we can… but should we? Kidney Int 57:735–737.

    PubMed  CAS  Google Scholar 

  135. Birkeland SA. 2001 Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 71:1089–1090.

    PubMed  CAS  Google Scholar 

  136. Torres A, Garcia S, Gomez A et al. 2004 Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 65:705–712.

    PubMed  CAS  Google Scholar 

  137. El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. 2003 Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 14:2975–2979.

    PubMed  CAS  Google Scholar 

  138. De Sevaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. 2002 Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 13:1608–1614.

    PubMed  Google Scholar 

  139. Torres A, Lorenzo V, Salido E. 2002 Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 13:551–558.

    PubMed  Google Scholar 

  140. Lausten GS, Lemser T, Jensen PK, Egfjord M. 1998 Necrosis of the femoral head after kidney transplantation. Clin Transplant 12:572–574.

    PubMed  CAS  Google Scholar 

  141. Massari PU. 1997 Disorders of bone and mineral metabolism after renal transplantation. Kidney Int 52:1412–1421.

    PubMed  CAS  Google Scholar 

  142. Parfitt AM. 1982 Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 8:92–112.

    PubMed  CAS  Google Scholar 

  143. Sperschneider H, Stein G. 2003 Bone disease after renal transplantation. Nephrol Dial Transplant 18:874–877.

    PubMed  Google Scholar 

  144. Reinhardt W, Bartelworth H, Jockenhovel F et al. 1998 Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 13:436–442.

    PubMed  CAS  Google Scholar 

  145. Messa P, Sindici C, Cannella G et al. 1998 Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 54:1704–1713.

    PubMed  CAS  Google Scholar 

  146. Bonarek H, Merville P, Bonarek M et al. 1999 Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 56:642–649.

    PubMed  CAS  Google Scholar 

  147. D’Alessandro AM, Melzer JS, Pirsch JD et al. 1989 Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery 106:1049–1055; discussion 1055–1056.

    PubMed  CAS  Google Scholar 

  148. Kerby JD, Rue LW, Blair H et al. 1998 Operative treatment of tertiary hyperparathyroidism: a single-center experience. Ann Surg 227:878–886.

    PubMed  CAS  Google Scholar 

  149. Topaloglu AK, Yildizdas D, Yilmaz HL et al. 2005 Bone calcium changes during diabetic ketoacidosis: a comparison with lactic acidosis due to volume depletion. Bone.

  150. Krieger NS, Bushinsky DA, Frick KK. 2003 Cellular mechanisms of bone resorption induced by metabolic acidosis. Semin Dial 16:463–466.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renal and Pancreas Transplant Division, Saint Barnabas Medical Center, Livingston, NJ

    Francis L. Weng MD, MSCE & Stanley Goldfarb (FACP)

  2. University of Pennsylvania School of Medicine, Suite 100 Stemmler, 3450 Hamilton Walk, 19104, Philadelphia, PA

    Stanley Goldfarb (FACP)

Authors
  1. Francis L. Weng MD, MSCE
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stanley Goldfarb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanley Goldfarb.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weng, F.L., Goldfarb, S. Related disorders of bone. Clinic Rev Bone Miner Metab 5, 39–52 (2007). https://doi.org/10.1007/BF02736670

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02736670

Key Words

Search

Navigation